LC
GOSS icon

Lindbrook Capital’s Gossamer Bio GOSS Stock Holding History

Lindbrook Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-273
Closed -$3K – 2897
2022
Q3 		$3K Buy
273
+36
+15% +$447 ﹤0.01% 1871
2022
Q2 		$2K Sell
237
-213
-47% -$1.65K ﹤0.01% 1964
2022
Q1 		$4K Buy
+450
New +$4.34K ﹤0.01% 1696
2021
Q4 		– Sell
-1,500
Closed -$19K – 2128
2021
Q3 		$19K Buy
+1,500
New +$13.8K 0.01% 765

Other funds holding GOSS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's GOSS Position: Q4 2022 in Review

Lindbrook Capital sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 273 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in GOSS in Q3 2021 and held it in 4 quarters. The position peaked at $19K in Q3 2021. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

  • Lindbrook Capital reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
  • Lindbrook Capital sold 273 Gossamer Bio shares in Q4 2022, an estimated $3K.
  • Lindbrook Capital first reported a position in Gossamer Bio in Q3 2021 and held it in 4 quarters.
  • Lindbrook Capital's Gossamer Bio position peaked at $19K in Q3 2021.
  • 120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.